Compare EPR Properties (EPR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs GeneDx Holdings Corp — how do they compare? EPR Properties trades at $54.8 (market cap $4.17B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: EPR Properties is far larger — about 2.1× GeneDx Holdings Corp's market cap, and EPR Properties pays a 6.84% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and GeneDx Holdings Corp for 19 Days on average.
| EPR | WGS | |
|---|---|---|
Market Cap | $4.17B | $2.02B |
Volume | 992,716 | 734,640 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $167.51 |
52-Week Low | $48.71 | $34.51 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | $7.68B | $2.05B |
Dividend Yield | 6.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $55.03, up 1.76% today, with a bearish technical signal but oversold RSI suggesting potential reversal. The REIT reported strong Q2 2026 EPS beat ($0.79 vs. $0.745 expected) and maintains a high gross margin of 91.41%. Recent news highlights its 6.5% dividend yield and diversification into theme parks and experiential properties, though 2026 net income is projected to decline to $263 million.
The stock offers value with a forward P/E of 17.44 and consensus price target of $65.50, implying 19% upside. Key risks include declining 2026 profitability, high leverage exposure, and sensitivity to interest rates. Analyst sentiment is mixed with 32% buy ratings, but institutional buying and oversold conditions support a cautious bullish outlook for income-focused investors.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
